Inventor · disambiguated record
Cecile M. Krejsa
Also filed as: KREJSA CECILE · KREJSA CECILE M
10 granted patents·8 pending applications·20 citations·filing 2008–2024
86Inventor score
Top patents by PatentIndex Score
18 records- 0193US9796721B2Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2016·Granted Oct 24, 2017·12 cites·17 claims
- 0282US2025090525A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2024·Application pending·0 cites
- 0382US2024199622A1Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 0481US7883700B2Anti-human IL-21 monoclonal antibodiesZYMOGENETICS INC·Filed 2008·Granted Feb 8, 2011·3 cites·6 claims
- 0578US11820777B2Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2022·Granted Nov 21, 2023·0 cites·27 claims
- 0678US10167291B2Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2017·Granted Jan 1, 2019·1 cites·28 claims
- 0774US8124089B2Anti-human IL-21 monoclonal antibodiesJASPERS STEPHEN R·Filed 2009·Granted Feb 28, 2012·1 cites·23 claims
- 0872US8361470B2Methods of treatment using anti-human IL-21 monoclonal antibodiesZYMOGENETICS INC·Filed 2012·Granted Jan 29, 2013·1 cites·18 claims
- 0972US8241629B2Anti-human IL-21 monoclonal antibodiesJASPERS STEPHEN R·Filed 2010·Granted Aug 14, 2012·1 cites·11 claims
- 1072US8226948B1Anti-human IL-21 monoclonal antibodiesJASPERS STEPHEN R·Filed 2012·Granted Jul 24, 2012·1 cites·8 claims
- 1171US11059829B2Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleateACERTA PHARMA BV·Filed 2020·Granted Jul 13, 2021·0 cites·42 claims
- 1271US10640509B2Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphomaACERTA PHARMA BV·Filed 2018·Granted May 5, 2020·0 cites·20 claims
- 1371US2022177476A1Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamideACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1469US2021322408A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1569US2019314369A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 1658US2018318304A1Methods of Using BTK Inhibitors to Treat DermatosesACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 1754US2017224688A1Methods of Using BTK Inhibitors to Treat DermatosesACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 1854US2017143712A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →